COMP <GO>
PFE vs LLY // EV/EBITDA & P/E VALUATION
Pfizer Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: PFE 4
— LLY 10
▲ EV/EBITDA & P/E VALUATION LEADER: PFE
LAST: $29.95 (+1.70%) • MKT CAP: $170.71B
valuation
19.7x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PFE VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PFE | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.30% | 83.64% | -9.34 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.10% | 32.36% | -27.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.7x | 36.4x | -16.72 | PFE | /valuation <GO> |
| Free Cash Flow Yield | 5.32% | 2.30% | +3.02 | PFE | /fcf-yield <GO> |
| Operating Margin | 15.10% | 40.21% | -25.11 | LLY | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 31.90% | -19.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -1.60% | 45.51% | -47.11 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.10 | 9.29 | -7.19 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.5 | 66.6 | -8.10 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.51 | +0.54 | PFE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.5x | 26.3x | -5.75 | PFE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $170.71B | $1.29T | -$1.12T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PFE REV | LLY REV | PFE GROSS % | LLY GROSS % | PFE FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.58B | $65.18B | 74.3% | 83.0% | $9.07B | $16.81B |
| FY 2024 | $63.63B | $45.04B | 71.9% | 81.3% | $9.84B | $8.82B |
| FY 2023 | $50.91B | $34.12B | — | 79.3% | $6.41B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PFE // BETA 1.05
LLY // BETA 0.51